What is HC Wainwright's Estimate for SCTX FY2026 Earnings?

Scribe Therapeutics logo with background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2026 EPS estimate for Scribe Therapeutics to a loss of $4.60 per share from a projected loss of $3.68; it maintained a Buy rating and $60 price target.
  • Scribe reported a quarterly loss of $0.68 per share, missing the $0.42 loss analysts expected, on revenue of $1.64 million.
  • MarketBeat reported a consensus “Moderate Buy” rating and average price target of $51.75, based on four Buy, one Hold and one Sell rating.
  • Interested in Scribe Therapeutics? Here are five stocks we like better.

Scribe Therapeutics Inc. (NASDAQ:SCTX - Free Report) - Analysts at HC Wainwright decreased their FY2026 earnings estimates for Scribe Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($4.60) for the year, down from their prior forecast of ($3.68). HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Scribe Therapeutics' current full-year earnings is ($3.68) per share. HC Wainwright also issued estimates for Scribe Therapeutics' Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.71) EPS, Q4 2027 earnings at ($0.80) EPS and FY2027 earnings at ($2.71) EPS.

A number of other brokerages also recently weighed in on SCTX. Guggenheim initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set a "buy" rating and a $50.00 price target on the stock. Zacks Research upgraded Scribe Therapeutics to a "hold" rating in a research note on Tuesday, September 1st. Leerink Partners began coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $37.00 price objective for the company. Wells Fargo & Company initiated coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They set an "overweight" rating and a $60.00 target price for the company. Finally, Weiss Ratings began coverage on Scribe Therapeutics in a report on Tuesday, October 20th. They set a "sell (e-)" rating on the stock. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.75.

Check Out Our Latest Analysis on SCTX

Scribe Therapeutics Price Performance

Shares of NASDAQ:SCTX opened at $15.37 on Tuesday. Scribe Therapeutics has a 52-week low of $13.50 and a 52-week high of $39.60. The firm has a market cap of $290.98 million and a P/E ratio of -1.41. The firm has a 50-day moving average price of $20.86.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The firm had revenue of $1.64 million for the quarter.

Institutional Trading of Scribe Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP bought a new position in Scribe Therapeutics in the 3rd quarter valued at about $12,675,000. Goldman Sachs Group Inc. acquired a new stake in Scribe Therapeutics during the third quarter worth approximately $398,000. Finally, State Street Corp bought a new stake in shares of Scribe Therapeutics during the third quarter worth approximately $3,150,000.

Scribe Therapeutics Company Profile

(Get Free Report)

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.

Read More

Earnings History and Estimates for Scribe Therapeutics (NASDAQ:SCTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Scribe Therapeutics Right Now?

Before you consider Scribe Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scribe Therapeutics wasn't on the list.

While Scribe Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines